Many recombinant poxviral vaccines are currently in clinical trials for cancer and infectious diseases. However, these agents have failed to generate T cell responses specific for recombinant gene products at levels comparable with T cell responses associated with natural viral infections. The recent identification of vaccinia-encoded CTL epitopes, including a new epitope described in this study, allows the simultaneous comparison of CTL responses specific for poxviral and recombinant epitope...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.
If you are the owner of this record, you can report an update to it here: Report update to this record